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Come early May, two-dozen or so gradu-
ate students, postdocs, engineers, and
physicians from across Latin America
will drop what they’re doing and converge
on the Fundacio´n Instituto Leloir in Bue-
nos Aires, Argentina’s renowned research
center, for an intensive 2 week training
course in stem cell research. Guiding
them will be 15 stem cell scientists from
North America as well as South America.
In a different country, a program of this
sort would be just another educational
offering. However, here in a place where
biologists have experienced a frustrating
half-century, PABSELA, for the Program
for the Advancement of Biomedical Sci-
ences Education in Latin America, is part
of a remarkable turnaround.
Now in its second year, PABSELA
arose out of an unusual collaboration be-
tween Argentina—its government, univer-
sity officials, and industry—and Harvard
Medical International (HMI). HMI has al-
lied itself with educational and clinical
programs before in South America, in
keeping with its mission of extending Har-
vard Medical School’s resources globally,
but this particular program represents its
first foray into research in that part of the
world. Given that Latin American students
are the main beneficiaries, the program’s
pivotal Argentine sponsor Fundacio´n
Crimson provides the hard cash, with
nearly 50% coming from the Argentine
government and the rest supplied by
companies and nonprofits. HMI, on its
side, donates numerous pro bono ser-
vices and materials, from facilitating the
provision of laboratory supplies to sup-
porting fund-raising efforts. In addition,
many of the instructors from Harvard
pay their way down.
‘‘There’s been a huge commitment from
the leadership of Harvard Medical Interna-
tional to make thishappen, because HMI is
basically not a foundation, not a charity. It
works on a fee-for-service basis and nor-
mally doesn’t do things on a pro bono
basis,’’ says Amanda Pullen, HMI’s Vice
President for Communications. The ex-
ception was made because ‘‘more than
just a need, there was an overwhelming
enthusiasm for this program to happen.’’
That enthusiasm came about when two
spirited Argentines, Miguel Velardez and
Estanislao Bachrach (pictured with Kevin
Eggan, center), then postdoctoral fellows
at Harvard Medical School, got it into their
heads to try and persuade Harvard to
launch a biosciences course in their
homeland. They were amazed by all the
technological and human resources
Harvard lavished on its foreign students.
‘‘But we wanted something totally differ-
ent. We wanted to take the resources
from Harvard to Latin America,’’ recalls
Bachrach.
Seeing this dream through took several
years of convincing and negotiating at
Harvard and at home. ‘‘When Miguel and
Estani first came to me, I was a junior fel-
low, barely a faculty member, but they
had tried every other faculty sponsor,
and I was the last stop,’’ recounts Harvard
Stem Cell Institute biologist Kevin Eggan.
Their idea seemed a bit off-the-wall, but
Eggan agreed to help them, and ever
since his belief in the program has soared.
Having taught in last year’s course,
Eggan, a PABSELA advisor, would do so
again—‘‘in a heartbeat,’’ he says. ‘‘The
thing that really motivates me to continue
to be involved, beside these two astonish-
ing people, Estani and Miguel, who have
so much enthusiasm for what they do, are
the stories of just how hard and danger-
ous it was to be a scientist in Argentina
up until just recently.’’
Miguel Velardez hadn’t yet been born
when ‘‘the night of the long canes’’ oc-
curred in July of 1966, but he talks about
it as if he lived through it. Sent by Argen-
tina’s military rulers, who viewed scien-
tists as left-wingers, troops descended
on the University of Buenos Aires’s school
of science, Velardez recounts. ‘‘They en-
tered and hit people with long sticks.
That’s a very memorable date, because
the next day roughly 90% of the most im-
portant scientists went to the airport and
moved away.’’ Democracy returned in
1983, yet the weak economy precluded
funding science. As recently as 1994,
the minister of the economy declared
that Argentina’s scientists should devote
their time to washing dishes.
Today, Bachrach, a geneticist, and
Velardez, a neuroscientist, codirect
PABSELA, while also serving as consul-
tants to HMI. Given that few Argentine
labs work on stem cells, the whole point
behind focusing their program on stem
cells has been to help move their coun-
try’s biosciences into the twenty-first
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cell lines created in Argentina ‘‘is zero,’’
says Velardez, and not because ES cell
research is prohibited, but simply be-
cause it hasn’t gained momentum. Argen-
tina does not regulate ES cell biology,
although that’s about to change. Argenti-
na’s first Minister of Science, Technology,
and Productive Innovation, cell biologist
Lino Baran˜ao, was appointed in Decem-
ber. Wasting no time, Baran˜ao has orga-
nized a stem cell advisory commission
made up of respected citizens from sev-
eral professions.
‘‘We want this commission to set up
rules on different aspects of stem cell re-
search,’’ says Baran˜ao, ‘‘so that the gov-
ernment can provide state-of-the-art infor-
mation’’ to the public. ‘‘Because there’s
a lot of confusion. Some companies are of-
fering miracle cures based on stem cells.’’
Not surprisingly, Baran˜ao sings
PABSELA’s praises. More than simply a
successful coupling of students and pro-
fessionals, he observes, the course allows
for an extremely efficient transfer of skills.
‘‘Consider,’’ he notes, ‘‘the cost of send-
ing students to the U.S. for training.’’
Last year’s rigorous schedule of 21 lec-
tures and 15 lab sessions was interrupted
by only 1 day off, when students and fac-
ulty spent a Sunday on an estancia in the
midst of the country’s natural treasure,
the pampas.
For Facundo Pelorosso, a student in last
year’s course, a high point during the lab
section was having the undivided attention
of Kornelia Polyak, a Dana-Farber cancer
stem cell researcher, for a solid week.
Polyak brought along samples comparing
normal and cancerous breast cells. ‘‘That
was incredible,’’ says Pelorosso.
Granted, even at the top-notch Leloir,
the laboratories often lack what North
American scientists consider standard
equipment. PABSELA’s U.S. teaching as-
sistants quickly learned from their Argen-
tine counterparts the importance of im-
provising. A shortage of test-tube racks,
for example, was surmounted by making
them with folded cardboard. There are
similar tales from Luis Leloir’s day. When
the roof of the library at the Instituto de In-
vestigaciones Bioquı´micas sprung a leak
that was too expensive to fix, Leloir con-
structed a gutter system made out of
cardboard, saving many a book.
‘‘You learn that the scientists there are
every bit as creative and intuitive and in-
novative as scientists here are. They’re
just limited by their resources,’’ notes
Kevin Eggan ‘‘In fact, in some ways that
makes them even more creative. I think
it’s interesting to interact with people like
that and to hear their ideas.’’
Stem cell research groups are few and
far between throughout South America.
Vero´nica Palma, a PABSELA faculty
member and developmental neurobiolo-
gist at the University of Chile, says that
when she returned from her postdoctoral
work in the U.S. in November 2003, ‘‘I
was the only one working on neural stem
cells for a long time.’’ Chile now has
a small but growing community of stem
cell researchers, and yet Palma laments
that most of her students ‘‘leave the coun-
try because they feel they can’t do what
they really want to do here.’’ The chance
to turn this trend around is the value of
PABSELA, in her opinion.
In Argentina, federal support for all the
sciences has been expanding since the
country’s former president, Ne´stor Kirch-
ner, doubled the spending for science
and technology, from 0.3 percent GDP
(gross domestic product) in 2003 to 0.65
percent in 2006. While still a small amount,
Lino Baran˜ao sees this as a vast improve-
ment and hopes for a further increase
to 1.0 percent by 2010. As for stem cell
research, Kirchner’s successor, his wife
CristinaFerna´ndezdeKirchner, isa fervent
backer. In fact, were it not for Mrs. Kirch-
ner’s helping hand in 2004, when she
was Argentina’s first lady and a senator,
PABSELA might never have materialized.
Coincidentally, just when Bachrach
and Velardez were discussing their idea
with anyone who would listen, Senator
Kirchner came to Boston for a meeting of
women leaders held in conjunction with
the Democratic National Convention. The
two postdocs invited her to Children’s
Hospital for a tour of the patient floors as
well as their labs. After showing her some
stem cells and explaining how they might
be used to treat diseases—maybe even
Chagas, an infectious disease that afflicts
9% of the Argentine population—she
turned to them and said, ‘‘Okay, what do
you guys want?’’ They delivered their ele-
vator pitch and completely sold her on
the idea of an Argentine-Harvard collabo-
ration. Two weeks later, a top Argentine
official called them to see how he could
help.
PABSELA was given a ceremonious
launch in September 2006 at the Casa
Rosada, the famous pink presidential pal-
ace. Some 150 dignitaries and scientists
attended, with Mrs. Kirchner, a few
months away from her inauguration, host-
ing the occasion. ‘‘It was wonderful to see
the public and private sectors after all
these years uniting around a scientific en-
deavor,’’ says Velardez. ‘‘To further build
a solid scientific base, we need even
more support from the Latino community
living and working in the United States.’’
Since the launch, stem cell fever keeps
spreading. PABSELA now hosts a Pan-
American conference each May for sev-
eral hundred scientists and physicians,
an event that assists local and foreign
companies in finding new markets in Latin
America. In March, a week-long course
for American and Argentine students fo-
cuses on stem cells and bioethics. Finally,
the government is collaborating with sev-
eral foundations, hospitals, companies,
and research institutes to develop stem
cell therapies in the areas of neurology,
cardiology, and oncology.
PABSELA stands to teach the latest
techniques to young Latin Americans,
and to facilitate the transfer of ideas and
technologies between hemispheres. No
goal is more important to its young codi-
rectors, however, than rebuilding Argenti-
na’s biomedical sciences back to their
former grandeur. Years of military dicta-
torship, they say, failed to wipe away
a rich tradition of scientific inquiry left by
such masters as Bernardo Houssay,
noted for his findings on the metabolism
of sugars; or Ce´sar Milstein, whose tech-
niques led to monoclonal antibodies; or
Salvador Mazza, a pioneer in infectious
diseases; or Luis Leloir, esteemed for his
work with sugar nucleotides.
‘‘We think our science and research is
10–20 years behind the United States,’’
Bachrach observes. ‘‘It’s not enough, but
PABSELA is one way of closing the gap.’’
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